CytoDyn's leronlimab in 350 mg weekly dose met endpoints in Phase 2 NASH trial
January 05 2022 - 8:38AM
Seeking Alpha
To read the full story on Seeking Alpha, click
here.
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Apr 2024 to May 2024
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From May 2023 to May 2024